Evidence map›Paper›PMID 36532056›Full record

ArticleFrontiers in immunology2022

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer.

Lishui Niu, Xiang Li, Li Meng, Yingying Zhang, Xin Wan, Di Jing, Qin Zhou, Rongrong Zhou

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lishui NiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Xiang LiDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Li MengDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, China.
Yingying ZhangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Xin WanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Di JingDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Qin ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Rongrong ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of immune checkpoint inhibitors (ICIs) has reshaped the landscape of advanced lung cancer treatment. The brain is the most common metastatic site for lung cancer. Whether conventional criteria can evaluate the intracranial response of ICIs remains unclear. Here, we report a well-documented case of intracranial necrosis confirmed by post-operative pathology after only one cycle of chemo-immunotherapy without any radiation therapy, which suggests that immunotherapy elicits strong anti-tumor responses for intracranial metastasis and promotes intracranial necrosis, resulting in a temporary increase in size of the target lesions. Still, the specific mechanisms and management strategies need to be further explored.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsNecrosisImmune Checkpoint Inhibitorsbrain metastasisbrain necrosiscase reportimmune checkpoint inhibitorslung cancer

Identifiers

PMID36532056
PMCPMC9752014
OpenAlexW4311065939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.